Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD

Keitaro Yokoyama, Hideki Hirakata, Takashi Akiba, Masafumi Fukagawa, Masaaki Nakayama, Kenichi Sawada, Yuji Kumagai, Geoffrey A. Block

Research output: Contribution to journalArticlepeer-review

83 Citations (Scopus)

Abstract

Background and objectives Ferric citrate hydrate is a novel iron-based phosphate binder being developed for hyperphosphatemia in patients with CKD. Design, setting, participants, & measurements A phase 3, multicenter, randomized, double blind, placebocontrolled study investigated the efficacy and safety of ferric citrate hydrate in nondialysis-dependent patients with CKD. Starting in April of 2011, 90 CKD patients (eGFR=9.2165.72 ml/min per 1.73 m2) with a serum phosphate$5.0 mg/dl were randomized 2:1 to ferric citrate hydrate or placebo for 12 weeks. The primary end point was change in serum phosphate from baseline to the end of treatment. Secondary end points included the percentage of patients achieving target serum phosphate levels (2.5-4.5 mg/dl) and change in fibroblast growth factor-23 at the end of treatment. Results Themean change in serumphosphatewas21.29 mg/dl (95%confidence interval,21.63 to20.96 mg/dl) in the ferric citrate hydrate group and 0.06mg/dl (95% confidence interval, 20.20 to 0.31 mg/dl) in the placebo group (P,0.001 for difference between groups). The percentage of patients achieving target serum phosphate levels was 64.9% in the ferric citrate hydrate group and 6.9% in the placebo group (P,0.001). Fibroblast growth factor-23 concentrations were significantly lower in patients treated with ferric citrate hydrate versus placebo (change from baseline [median], 2142.0 versus 67.0 pg/ml; P,0.001). Ferric citrate hydrate significantly increased serum iron, ferritin, and transferrin saturation compared with placebo (P=0.001 or P,0.001). Five patients discontinued active treatment because of treatment-emergent adverse eventswith ferric citrate hydrate treatment versus one patient with placebo. Overall, adverse drug reactions were similar in patients receiving ferric citrate hydrate or placebo, with gastrointestinal disorders occurring in 30.0%of ferric citrate hydrate patients and 26.7%of patients receiving placebo. Conclusion In patients with nondialysis-dependent CKD, 12-week treatment with ferric citrate hydrate resulted in significant reductions in serum phosphate and fibroblast growth factor-23 while simultaneously increasing serum iron parameters.

Original languageEnglish
Pages (from-to)543-552
Number of pages10
JournalClinical Journal of the American Society of Nephrology
Volume9
Issue number3
DOIs
Publication statusPublished - 2014 Mar 7
Externally publishedYes

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Fingerprint

Dive into the research topics of 'Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD'. Together they form a unique fingerprint.

Cite this